◆ NeutralVACHVACHUVACHW

VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

Benzinga·
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

VERAXA Biotech AG successfully completed its business combination with Voyager Acquisition Corp and will begin trading on NASDAQ under ticker VRXA on June 11, 2026. The company secured $27.5 million in senior secured note financing and up to $50 million in share purchase agreements to advance its pipeline of BiTAC-TCE and BiTAC-ADC cancer therapies. VERAXA presented promising preclinical data at AACR 2026 demonstrating superior safety profiles and matching efficacy compared to traditional TCEs.

Read Full Article at Benzinga
← Back to Financial Intelligence